New Notices
- New Notice of Intent to Revise: Albuterol Inhalation Solution (posted 29-Sep-2023)
- New Pending Revision Notice: Rivaroxaban Tablets (posted 29-Sep-2023)
- New Pending Revision Notice: Rotigotine Transdermal System (posted 29-Sep-2023)
- New General Announcement: Changes to USP's Description and Solubility Reference Table (posted 29-Sep-2023)
- New General Announcement: Chemical Information Updates (posted 29-Sep-2023)
- New Notice of Intent to Revise: Monographs Affected by Revision to <789> Particulate Matter in Ophthalmic Solutions (posted 29-Sep-2023)
- New General Announcement: Polyethylene Glycol (posted 29-Sep-2023)
- New General Announcement: USP-NF Online: Official Dates for Monographs in Redesigned Format (posted 29-Sep-2023)
- New Pending Revision Notice: Propranolol Hydrochloride Tablets (posted 25-Aug-2023)
- New Notice of Intent to Revise: <621>Chromatography (posted 25-Aug-2023)
- New Notice of Intent to Revise: Gramicidin (posted 25-Aug-2023)
- New Notice of Intent to Revise: Norgestimate (posted 25-Aug-2023)
- New Notice of Intent to Revise: Starch TS (posted 25-Aug-2023)
- New Notice of Intent to Revise: Zinc Family of Monographs (posted 25-Aug-2023)
- New General Announcement: Missing Reference Standards Corrected in Five USP-NF Monographs (posted 25-Aug-2023)
- New General Announcement: Bacterial Endotoxins Test Using Recombinant Reagents (posted 22-Aug-2023)
- New Notice of Intent to Revise: Dutasteride and Tamsulosin Hydrochloride Tablets (posted 28-Jul-2023)
- New Notice of Intent to Revise: Magaldrate Family of Monographs (posted 28-Jul-2023)
- New Notice of Intent to Revise: Methscopolomine Bromide Tablets (posted 28-Jul-2023)
- New Notice of Intent to Revise: Zinc Sulfate Injection (posted 28-Jul-2023)